FDA Clearance Tracker · P080011-S004
BIOFINITY CONTACT LENSES
Last checked: Nov 20, 2026Latest source record: Mar 23, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Mar 23, 2011
Approved
Time to decision
27 days
Received Feb 24, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P080011-S004
- Device name
- BIOFINITY CONTACT LENSES
- Applicant
- CooperVision, Inc.
- Applicant location
- San Ramon, CA
- Received
- Feb 24, 2011
- Decided
- Mar 23, 2011
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P080011
Device type
- Device type
- Lenses, soft contact, extended wear (LPM)
- Device class
- Class III
- Regulation
- 21 CFR 886.5925
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
ALTERNATE LABELING AND PACKING SITE LOCATED AT COOPERVISION INC. IN WEST HENRIETTA, NEW YORK.
Source documents
Other decisions for CooperVision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K234127 · Decided Jan 25, 2024 · 28 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.